A Phase I, open-label clinical study evaluating the pharmacodynamics, pharmacokinetics, safety, and tolerability of a single-dose intravenous administration of CG-0255 besylate for injection in healthy adult subjects in China
Latest Information Update: 16 Mar 2026
At a glance
- Drugs CG 0255 (Primary)
- Indications Cardiovascular disorders
- Focus Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 16 Mar 2026 New trial record